Brief ReportThe R230C variant of the ATP binding cassette protein A1 (ABCA1) gene is associated with a decreased response to glyburide therapy in patients with type 2 diabetes mellitus
Introduction
The ABCA1 transporter transfers cholesterol from the cell membrane to plasma apolipoprotein A-I. This action constitutes the initial step in the synthesis of high-density lipoproteins [1]. There are over 20 known ABCA1 polymorphisms [2]. One such variant, the R230C allele (rs9282541) is common in the Mexican population; a population-based survey, reported a prevalence of 18.7% among participants [3], [4]. The magnitude of the effect of the C230 variant (− 5.73 ± 1.4 mg/dl) on the concentration of HDL-C is greater than that observed with other polymorphisms (usually less than 2 mg/dl). In addition, two cross-sectional studies have shown that the R230C variant of ABC-A1 is associated with type 2 diabetes. This transporter appears to play a role in the regulation of insulin secretion [5], [6]. A beta cell specific abc-a1 knockout mouse has impaired glucose tolerance due to decreased insulin secretion [7]. The lack of β-cell ABCA1 results in impaired depolarization-induced exocytotic fusion of insulin granules, disturbances in membrane microdomain organization and abnormal Golgi and insulin granule morphology [8], [9]. Furthermore, impaired insulin secretion has been reported in persons with ABCA1 loss-of-function mutations [10].
Sulfonylureas stimulate insulin secretion from pancreatic beta cells, and are among the first line treatments of hyperglycemia. The response to these drugs shows inter-individual variability but little is known regarding sulfonylurea pharmacogenomics; variants of ABCC8, KCNJ11, IRS1, TCF7L2, and NOS1AP have been associated with changes in the sulfonylurea response [11].
In this report, our hypothesis is that persons with type 2 diabetes who have the R230C variant of ABCA1 may have a decreased hypoglycemic response to a sulfonylurea, compared to participants with the wild type variant (R230R).
Section snippets
Materials and methods
This was a single blind controlled study in which the hypoglycemic response to glyburide is compared between two groups of persons with type 2 diabetes during a 16 week treatment period. One group had the R230C variant of ABC-A1 and the other had the R230R variant. Both groups were matched for gender, age (± 5 years) and BMI (± 2 kg/m2). Each person with the risk allele was matched to three others with the wild type variant. Participants were Mexican mestizos aged 20–79 years, with a BMI between 18
Results
Our study sample included 17 individuals with the R230C variant and 68 subjects with the R230R variant. Both groups were successfully matched by age, gender and body mass index (Table 1). One subject in the R230R group died unexpectedly; the cause of death was unrelated to the study intervention. No further subjects were lost during the study. No severe hypoglycemic events were reported. Adherence to therapy was above 70% in all participants regardless of allelic variant.
After 16 weeks of
Discussion
Our data show that persons with type 2 diabetes who have the ABCA1 R230C polymorphism require a higher glyburide dose to achieve similar glucose lowering as matched subjects with the wild type variant. This observation suggests that ABCA1 is involved in the pharmacogenomics of type 2 diabetes. The R230C allele was independently associated with the glyburide dosage, even after adjusting for FPG, BMI and adherence to therapy.
ABC-A1 plays an important role in the regulation of insulin secretion in
Author contributions
C.A.A-S designed the study and wrote the manuscript. L.L.M-H researched data and contributed to the discussion. MC-B, M.R.R-M and M.L.O-S researched data. R.M. reviewed/edited the manuscript. R.M-S.and M.T.T-L. contributed to the discussion and reviewed/edited the manuscript. No conflict of interest is declared by the authors.
Funding
The study was conducted with support provided by Department of Research and Postgraduate Studies, Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico City, Mexico.
Conflict of interest
None of the authors have a financial interest related to this work.
Acknowledgments
We express our gratitude to the personnel of the Endocrinology and Metabolism department who provided technical and logistic support. We also express our gratitude to our patients.
References (17)
- et al.
The non-synonymous Arg230Cys variant (R230C) of the ATP-binding cassette transporter A1 is associated with low HDL cholesterol concentrations in Mexican adults: a population based nation wide study
Atherosclerosis
(2011) - et al.
Association of the ABCA1 gene polymorphisms with type 2 DM in a Japanese population
Biochem Biophys Res Commun
(2005) Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy
Clin Ther
(2004 Nov)- et al.
ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease
Physiol Rev
(2005) - et al.
Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis
Annu Rev Nutr
(2006) - et al.
Hypoalphalipoproteinemia in populations of Native American ancestry: an opportunity to assess the interaction of genes and the environment
Curr Opin Lipidol
(2009) - et al.
The ABCA1 R230C variant affects HDL cholesterol levels and body mass index in the Mexican population: association with obesity and obesity-related comorbidities
Diabetes
(2007) - et al.
Association of the ABCA1 R230C variant with early-onset type 2 diabetes in the Mexican population
Diabetes
(2008)
Cited by (11)
Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis
2021, Progress in Lipid ResearchCitation Excerpt :In contrast, decreased ABCA1 expression results in the impairment in cholesterol efflux and aggravates cholesterol accumulation in the liver, thereby exacerbating NAFLD [116,117]. In addition, ABCA1 mutations or its variants have been reported be closely associated with NAFLD-related risk factors, such as type 2 diabetes, obesity, and metabolic syndrome [118–121]. Consequently, these studies indicate that ABCA1-mediated cholesterol efflux may contribute to a decrease in lipid storage in hepatocytes although more data are required to establish its exact role in NAFLD.
ABCA1 genetic polymorphisms and type 2 diabetes mellitus and its complications
2017, Meta GeneCitation Excerpt :ABCA1 is a determinant of HDL levels. The rs9282541 is reported to be associated with susceptibility to T2DM (Villarreal-Molina et al., 2008; Aguilar-Salinas et al., 2013) or HDL levels in the patients from Mexico (Aguilar-Salinas et al., 2004; Lara-Riegos et al., 2004), but this variant was ineffective in subjects from Colombia (Campbell et al., 2012), Malaysia (Haghvirdizadeh et al., 2015) or other study from Mexico (Miranda-Lora et al., 2017) (Table 4). The CT carriers from Mexico were more susceptible to early onset of T2DM (Villarreal-Molina et al., 2008).
Novel Association of the R230C Variant of the ABCA1 Gene with High Triglyceride Levels and Low High-density Lipoprotein Cholesterol Levels in Mexican School-age Children with High Prevalence of Obesity
2015, Archives of Medical ResearchCitation Excerpt :This finding may be related with our result because there are different body distribution between children and adults; nonetheless, additional studies are necessary. Although some reports have shown a tendency of higher triglycerides in those subjects with the risk variant genotype in a dominant model (R230C/C230C), their results failed to reach statistical significance (7,8,31,32). For this reason, more studies are needed with larger sample sizes to validate this finding.
ATP-binding cassette transporter A1: From metabolism to neurodegeneration
2014, Neurobiology of DiseaseCitation Excerpt :A highly frequent non-synonymous variant of ABCA1 (R230C) was identified in a Mexican population and shown to associate with obesity and type 2 diabetes (Villarreal-Molina et al., 2008). Also in a Mexican population it was reported that diabetic patients harboring this mutation needed a higher dose of glyburide to control glucose level (Aguilar-Salinas et al., 2013). However, a recent study examining several genetic variants in ABCA1 and ABCG1 did not find an association with an increased risk of type 2 diabetes (Schou et al., 2012).
ABCA1 variant rs9282541 is associated with metabolic syndrome in Maya children
2024, Annals of Human GeneticsPharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review
2022, Journal of Diabetes and Metabolic Disorders
The study is registered in ClinicalTrials.gov (NCT01456650).